STOCK TITAN

PacBio Announces the Retirement of David Botstein, Ph.D., from its Board of Directors

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
management
Rhea-AI Summary
PacBio (NASDAQ: PACB) announced the retirement of David Botstein, Ph.D., a member of PacBio's Board of Directors, effective December 7, 2023. Christian Henry, President and CEO, expressed gratitude for Botstein's contributions to the company's technological innovation and leadership.
Positive
  • None.
Negative
  • None.

MENLO PARK, Calif., Dec. 11, 2023 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that David Botstein, Ph.D., a member of PacBio's Board of Directors, has retired from his position effective December 7, 2023.  

"I would like to thank David for his dedication to PacBio since he joined the Board in 2012," said Christian Henry, President and Chief Executive Officer. "His deep understanding of genomics and broad experience in technological innovation in the field has made him a valuable leader as PacBio launched and scaled its technology to where it is today."

"It has been an honor to work alongside the PacBio leadership team for more than 11 years, and I have never been more excited about the prospects for PacBio and its technology than I am today," added David Botstein. "I leave the Board with a world-class leadership team that I believe will continue to execute on its goal of becoming a multi-omic leader in the life sciences industry."  

About PacBio

Pacific Biosciences of California, Inc. (NASDAQ: PACB) is a premier life science technology company that is designing, developing, and manufacturing advanced sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. Our products and technology under development stem from two highly differentiated core technologies focused on accuracy, quality, and completeness, which include our existing HiFi long-read sequencing technology and our emerging short-read Sequencing by Binding (SBB™) technology. Our products address solutions across a broad set of applications, including human genomics, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. For more information, please visit www.pacb.com and follow @PacBio.

PacBio products are provided for research use only. Not for use in diagnostic procedures.

Contacts

Investors:
Todd Friedman
650.521.8450
ir@pacb.com 

Media:
Lizelda Lopez
pr@pacb.com 

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/pacbio-announces-the-retirement-of-david-botstein-phd-from-its-board-of-directors-302010982.html

SOURCE Pacific Biosciences of California, Inc.

FAQ

Who retired from PacBio's Board of Directors?

David Botstein, Ph.D.

When did David Botstein retire from his position at PacBio?

December 7, 2023.

Who expressed gratitude for David Botstein's contributions to PacBio?

Christian Henry, President and CEO.

What is PacBio's ticker symbol?

PACB.

What is PacBio's area of expertise?

High-quality, highly accurate sequencing solutions.

Pacific Biosciences of California, Inc.

NASDAQ:PACB

PACB Rankings

PACB Latest News

PACB Stock Data

541.96M
266.44M
2.8%
101.74%
18.31%
Analytical Laboratory Instrument Manufacturing
Manufacturing
Link
United States of America
MENLO PARK

About PACB

pacbio develops comprehensive solutions for scientists that propel the field of genomics, improve science and research, and create positive impact globally. we provide sophisticated genomic analysis systems that deliver invaluable insights for scientists who strive to resolve complex genetic challenges. our strength comes from the dedication of our people, who are fueled by a desire to effect real, positive change. with a focus on the future and an experienced, passionate team, we are motivated to continue to redefine what is possible in genomics.